Affimed Mourns Passing of Chief Financial Officer Dr. Florian Fischer
February 03 2020 - 7:30AM
Heidelberg, Germany, February 3, 2020 – Affimed
N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company
committed to giving patients back their innate ability to fight
cancer, today announced that Dr. Florian Fischer, Chief Financial
Officer (CFO) of Affimed, passed away this weekend due to
complications related to neoplasia.
Affimed CEO Dr. Adi Hoess said, “Everyone at
Affimed is deeply saddened by this loss. Florian was a great
partner and brought passion, leadership, commitment, as well as
strong financial acumen to our company for 15 years. I am
personally grateful to Florian for the significant role he played
in Affimed becoming a NASDAQ-listed, publicly-traded biotechnology
company. Affimed is currently in a strong financial position
largely due to his leadership. All of us at Affimed will miss
his warm-heartedness, energy, enthusiasm and sense of humor. Our
sincere condolences go out to his family and friends.”
Chairman of the supervisory board at Affimed,
Dr. Thomas Hecht, said, “Florian was an incredibly knowledgeable
and skilled CFO, as well as a wonderfully kind and caring man. He
was a dedicated and conscientious leader and part of the soul of
Affimed. He will be widely missed both personally and
professionally. The supervisory board, management team, and
employees of Affimed deeply mourn his passing, and extend our
heartfelt sympathy to his family.”
Dr. Fischer joined Affimed in 2005 as CFO on a
part-time basis, and transitioned into the full-time CFO position
at the company’s initial public offering in 2014. Prior to joining
Affimed, Dr. Fischer served as CFO for Activaero GmbH and Vivendy
Ltd., and was founder of MedVenture Partners.
Affimed has commenced a process with an
executive search firm for a new permanent CFO. As part of the
transition plan, the company announced that the experienced
financial and biotechnology industry executive Harry Welten will
assume the operating responsibilities of the CFO during the search
and will continue to operate in that capacity until a permanent
successor has been appointed. Mr. Welten has more than 20 years of
U.S. and European executive management experience in the
biotechnology, pharmaceutical and banking industries, and has
served as CFO for several publicly-traded biotechnology companies,
including Kuros Biosciences AG (formerly Cytos Biotechnology
AG), Horizon Pharma AG (formerly Nitec Pharma AG) and Arpida
AG.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The Company is developing single and
combination therapies to treat hematologic and solid tumors. For
more information, please visit www.affimed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements appear in a number of
places throughout this release and include statements regarding our
intentions, beliefs, projections, outlook, analyses and current
expectations concerning, among other things, the value of our ROCK®
platform, our ongoing and planned preclinical development and
clinical trials, our collaborations and development of our products
in combination with other therapies, the timing of and our ability
to make regulatory filings and obtain and maintain regulatory
approvals for our product candidates, our intellectual property
position, our collaboration activities, our ability to develop
commercial functions, clinical trial data, our results of
operations, cash needs, financial condition, liquidity, prospects,
future transactions, growth and strategies, the industry in which
we operate, the trends that may affect the industry or us and the
risks, uncertainties and other factors described under the heading
“Risk Factors” in Affimed’s filings with the U.S. Securities and
Exchange Commission. Given these risks, uncertainties and other
factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future.
Affimed Investor and Media
Contact:
Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024